Literature DB >> 34191060

Stereotactic Radiosurgery for Pituitary Carcinoma.

Gautam U Mehta1, Ian E McCutcheon2.   

Abstract

A pituitary carcinoma (PC) is a rare neoplasm, accounting for only 0.2% of pituitary tumors, and is defined by the presence of noncontiguous metastatic disease. Its management requires a multimodal approach including surgery, irradiation, and medical therapy. Stereotactic radiosurgery (SRS) by means of the Gamma Knife or CyberKnife may be considered potentially useful in such cases. It has mainly been applied for localized metastases and symptomatic lesions, but it may also be effective in control of aggressive tumor growth at the primary site after sufficient surgical debulking of the lesion. Given the infrequency of PC and their heterogeneous nature with regard to the histopathological type, local extension, and location of metastases, large clinical series have not been compiled to date. While, in such cases, SRS is certainly not curative and does not prevent disease progression, it is quite reasonable to incorporate this treatment option into a multimodal management strategy and apply it judiciously at the treating clinician's discretion on a case-by-case basis.

Entities:  

Keywords:  CyberKnife radiosurgery; Gamma Knife radiosurgery; Metastatic disease; Pituitary adenoma; Pituitary carcinoma; Stereotactic radiotherapy

Year:  2021        PMID: 34191060     DOI: 10.1007/978-3-030-69217-9_5

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  3 in total

Review 1.  Stereotactic radiosurgery for malignant extracerebral intracranial tumors: patient selection, efficacy, and technical nuances.

Authors:  Ian E McCutcheon
Journal:  Acta Neurochir Suppl       Date:  2013

Review 2.  Pituitary carcinoma: a clinicopathological review.

Authors:  Bernd W Scheithauer; Ozlem Kurtkaya-Yapicier; Kalman T Kovacs; William F Young; Ricardo V Lloyd
Journal:  Neurosurgery       Date:  2005-05       Impact factor: 4.654

3.  A case of nonfunctioning pituitary carcinoma that responded to temozolomide treatment.

Authors:  Haruko Morokuma; Takao Ando; Takuya Hayashida; Ichiro Horie; Naoko Inoshita; Fumi Murata; Ikuko Ueki; Kan Nakamura; Misa Imaizumi; Toshiro Usa; Atsushi Kawakami
Journal:  Case Rep Endocrinol       Date:  2012-10-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.